Skip to content

US · ZLAB · BIOTECHNOLOGY

Zai Lab Limited (ZLAB) intrinsic value and stock valuation

$21.03as of 2026-11-21 · Mkt cap 2.07B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zai Lab Limited DCF and intrinsic value

InvestorsCraft values ZLAB with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ZLAB’s statements →

Zai Lab Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Shanghai, SH 201210 zailaboratory.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$460.2M+56.5% 5y CAGRd
20152025
Net income
-$-175.54M
20152025
Free cash flow
-$-158.89M
20152025
Total equity
$715.5M-9.4% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$460.2M$399M$266.7M$215M$144.3M
Operating income-$-223.57M-$-282.12M-$-366.57M-$-404.36M-$-700.06M
Net income-$-175.54M-$-257.1M-$-334.62M-$-443.29M-$-704.47M
EPSd-$-1.6M-$-2.6M-$-34.64M-$-46.27M-$-75.75M
Operating cash flow-$-150.79M-$-214.87M-$-198.18M-$-367.64M-$-549.23M
Capital expenditure-$-8.1M-$-61.52M-$-8.49M-$-24.98M-$-18.95M
Free cash flow-$-158.89M-$-276.39M-$-206.67M-$-392.63M-$-568.18M
Total assets$1.17B$1.19B$1.04B$1.22B$1.61B
Total debt$224.3M$153.5M$15.2M$20.4M$15.5M
Net debt-$-455.31M-$-296.2M-$-775M-$-988.08M-$-948.56M
Total equity$715.5M$840.9M$796.1M$1.05B$1.38B
Cash and short-term investments$689.6M$779.7M$806.5M$1.01B$1.41B
Income statement
20252024202320222021
Revenue$460.2M$399M$266.7M$215M$144.3M
Cost of revenue$191.1M$147.9M$95.8M$74M$52.2M
Gross profit$269.1M$251.1M$170.9M$141M$92.1M
Research and development expenses$220.9M$234.5M$265.9M$286.4M$573.3M
Selling, general and administrative expenses$277.6M$298.7M$281.6M$259M$218.8M
Other expenses-$-5.86M$0.00-$-10M$0.00$0.00
Operating expenses$492.7M$533.3M$537.5M$545.4M$792.1M
Cost and expenses$683.7M$681.1M$633.3M$619.4M$844.4M
Interest income$33.1M$37.1M$39.8M$14.6M$2.19M
Interest expense$5.21M$2.25M$0.00$0.00$0.00
Depreciation and amortization$15M$20.3M$9.03M$8.23M$6.49M
Ebitda-$-158.25M-$-234.57M-$-365.11M-$-434.84M-$-689.46M
Operating income-$-223.57M-$-282.12M-$-366.57M-$-404.36M-$-700.06M
Total other income/expenses, net$45.1M$25M$32M-$-38.93M-$-3.35M
Income before tax-$-178.46M-$-257.1M-$-334.62M-$-443.29M-$-703.41M
Income tax expense-$-2.93M$0.00$0.00$0.00$1.06M
Net income-$-175.54M-$-257.1M-$-334.62M-$-443.29M-$-704.47M
Weighted average shares outstanding$109.5M$99M$9.66M$9.58M$9.3M
Weighted average diluted shares outstanding$109.5M$99M$9.66M$9.58M$9.3M
Balance sheet
20252024202320222021
Cash and short-term investments$689.6M$779.7M$806.5M$1.01B$1.41B
Net receivables$106.1M$89.4M$65.3M$48.6M$54.8M
Inventory$74.8M$39.9M$44.8M$31.6M$19M
Total current assets$1.02B$1.05B$939.6M$1.12B$1.5B
Property, plant and equipment, net$66.5M$69.5M$68.7M$78.8M$58.3M
Goodwill and intangible assets$76.1M$58.9M$16.5M$8.4M$9.66M
Long-term investments$0.00$3.12M$9.22M$6.43M$15.6M
Total non-current assets$153.1M$135.3M$96.7M$95.8M$109.1M
Total assets$1.17B$1.19B$1.04B$1.22B$1.61B
Accounts payable$141.6M$100.9M$113M$66M$126.2M
Short-term debt$210.9M$139.8M$7.1M$7.05M$5.93M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$416.2M$299.4M$203.1M$139.8M$192.9M
Long-term debt$13.4M$13.7M$8.05M$13.3M$9.61M
Deferred revenue, non-current$0.00$31.4M$28.7M$21.4M$27.5M
Total non-current liabilities$40.7M$45.5M$37.1M$34.7M$37.1M
Capital lease obligations$6.34M$21.8M$15.2M$20.4M$15.5M
Total liabilities$456.9M$344.9M$240.2M$174.5M$230M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-2.63B-$-2.45B-$-2.2B-$-1.86B-$-1.42B
Accumulated other comprehensive income (loss)$29.7M$50.5M$37.6M$25.7M-$-23.64M
Total equity$715.5M$840.9M$796.1M$1.05B$1.38B
Total investments$10M$333.1M$25.5M$6.43M$460.6M
Total debt$224.3M$153.5M$15.2M$20.4M$15.5M
Net debt-$-455.31M-$-296.2M-$-775M-$-988.08M-$-948.56M
Cash flow statement
20252024202320222021
Net income-$-175.54M-$-257.1M-$-334.62M-$-443.29M-$-704.47M
Depreciation and amortization$15M$11.9M$9.03M$8.23M$6.49M
Stock-based compensation$65.6M$70.7M$79.6M$61.3M$40.7M
Change in working capital-$-51.51M-$-68.39M$39.6M-$-66.25M$23.1M
Accounts receivable-$-26.72M-$-26.58M-$-17.69M$25.1M-$-42.32M
Inventory-$-47.15M$3.9M-$-14.91M-$-15.38M-$-7.17M
Accounts payable$19.9M-$-2.21M$36.8M-$-53.77M$63.5M
Net cash provided by operating activities-$-150.79M-$-214.87M-$-198.18M-$-367.64M-$-549.23M
Investments in property, plant and equipment-$-8.1M-$-5.66M-$-7.21M-$-24.59M-$-18.95M
Acquisitions, net$0.00$30K$0.00$0.00-$-30M
Net cash used for investing activities$307.9M-$-375.19M-$-10.78M$420M$250M
Common stock issued$12.9M$217.4M$0.00$0.00$818.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$72.4M$349.9M-$-6.43M-$-1.73M$820.2M
Net change in cash$229.9M-$-240.48M-$-218.01M$44.4M$522M
Cash at end of period$780.7M$550.8M$791.3M$1.01B$964.9M
Operating cash flow-$-150.79M-$-214.87M-$-198.18M-$-367.64M-$-549.23M
Capital expenditure-$-8.1M-$-61.52M-$-8.49M-$-24.98M-$-18.95M
Free cash flow-$-158.89M-$-276.39M-$-206.67M-$-392.63M-$-568.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zai Lab Limited

        Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.

        CEO
        Ying Du
        Employees
        1.78K
        Beta
        0.76

        Explore

        Frequently asked questions

        What is the intrinsic value of Zai Lab Limited (ZLAB)?

        Zai Lab Limited (ZLAB) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ZLAB undervalued?

        ZLAB trades at a price of $21.03 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.